Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive three-dimensional (3D) telomere analytics platform, to provide healthcare workers with actionable information regarding disease aggressiveness and influence treatment decisions for cancer patients.

Telo Genomics’ lead product in development for smoldering multiple myeloma targets to address a critical unmet need in the management of multiple myeloma, a deadly blood cancer, with a total addressable market of over 500,000 tests per year.

Telo Genomics’ ground-breaking proprietary platform TeloView® utilizes liquid biopsy and single cell analytics to empower its artificial intelligence and machine learning algorithm that quantifies genomic disease signals, unleashing game-changing predictive power.